LIXTW

LIXTW

USD

Lixte Biotechnology Holdings Inc. Warrants

$0.030+0.000 (0.000%)

Reaalajas hind

Healthcare
Biotehnoloogia
Ameerika Ühendriigid

Hinnagraafik

Graafiku andmed pole saadaval

Põhinäitajad

Turunäitajad
Ettevõtte fundamentaalnäitajad
Kauplemisstatistika

Turunäitajad

Avatud

$0.030

Kõrge

$0.030

Madal

$0.030

Maht

N/A

Ettevõtte fundamentaalnäitajad

Tööstusharu

Biotehnoloogia

Riik

United States

Kauplemisstatistika

Keskmine maht

0.00M

Börs

NCM

Valuuta

USD

52 nädala vahemik

Madal $0.019Praegune $0.030Kõrge $0.094

Seotud uudised

GlobeNewswire

LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100

Pre-Clinical Study in Collaboration with Netherlands Cancer Instituteis in addition to LIXTE's Ongoing Clinical Trials for Ovarian and Colorectal Cancers PASADENA, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- LIXTE

Vaata rohkem
LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100
GlobeNewswire

LIXTE Biotechnology Provides Update On Progress with Proprietary Compound, LB-100, to Treat Ovarian and Colorectal Cancer

-Started Two New Clinical Trials, Collaborating with MD Anderson and The Netherlands Cancer Institute for Treatment of Ovarian and Colorectal Cancer- -Received Exclusive Patent License Agreement with the NIH on

Vaata rohkem
LIXTE Biotechnology Provides Update On Progress with Proprietary Compound, LB-100, to Treat Ovarian and Colorectal Cancer